Design and testing of compounds targeting GK and PPARγ to lower blood sugar

Three compounds demonstrated high potency toward glucokinase and moderate activity toward PPARγ.

• A multi-target strategy was employed to develop agents for treating type 2 diabetes mellitus.
• Dual-target molecules were created by integrating features from known glucokinase activators and PPARγ agonists.
• The dual-target agents were assessed for their ability to activate transcription for both GK and PPARγ.
• Preliminary analysis of structure-activity relationships was conducted for the synthesized compounds.
• Molecular docking simulations were performed to explore the binding modes of one of the most effective compounds.

Simplified